J&J discontinues late-stage study for bladder cancer drug-March 2024-www.financetom.com

J&J discontinues late-stage study for bladder cancer drug

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

J&J discontinues late-stage study for bladder cancer drug

Oct 7, 2024 6:26 PM

Oct 7 (Reuters) - Johnson & Johnson ( JNJ ) said on

Monday it has discontinued a late-stage study testing its

experimental drug to treat a type of bladder cancer as the drug

did not show superior benefits compared to chemoradiation.

Previous page： Coronavirus puts brakes on sports car maker Ferrari Next page： Karnataka sees liquor sales worth Rs 45 crore on day 1 as wine shops open

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Coronavirus puts brakes on sports car maker Ferrari

May 4, 2020

Luxury sports car maker Ferrari cut its 2020 core profit forecast on Monday due to disruption caused by the coronavirus...

Karnataka sees liquor sales worth Rs 45 crore on day 1 as wine shops open

May 4, 2020

According to the Excise Department, around 3.9 lakh litre of beer was sold and 8.5 lakh litre of Indian-made foreign liquor on day one of the restrictions being lifted.

RIL goes on multi-billion-dollar deals overdrive amid tepid fund-raising climate

May 4, 2020

Jio Platfom's Facebook and Silver Late deals reinforce RIL’s ability to monetise its assets while also deleveraging on its way to becoming a zero net debt company in 2020.

Reliance Industries' net debt to fall 67% post Silver Lake deal

May 4, 2020

Reliance Industries (RIL) net debt will fall 67 percent after the Silver Lake investment, which comes on the heels of the massive deal with Facebook and rights issue announcement during quarterly earnings.